Nanotechnology - Microbiota synergy in cancer immunotherapy.

This review study examined how emerging nanotechnology can work together with the gut microbiome (the trillions of bacteria living in our intestines) to improve cancer treatment outcomes. Researchers analyzed current scientific understanding of how gut bacteria communicate with the immune system and influence cancer progression. They found that gut microbiota plays a crucial role in determining whether cancer immunotherapy drugs work effectively, but traditional methods of modifying gut bacteria—like fecal transplants or antibiotics—have significant limitations in targeting specific areas. The study reveals that nanotechnology offers promising solutions by enabling precise delivery of treatments directly to gut bacteria and tumor sites. These tiny engineered particles can reshape the immune environment around tumors, making immunotherapy more effective. Additionally, nanotechnology can help overcome drug resistance that often develops during chemotherapy, radiation, and targeted cancer therapies. The technology can also work synergistically with beneficial probiotics and other therapeutic agents. While this research doesn't directly involve acupuncture, it's important for cancer patients to understand how the gut-immune system connection affects treatment outcomes. Acupuncture practitioners working with cancer patients may find this information valuable when considering integrative approaches that support gut health and immune function during conventional cancer treatment. Patients interested in acupuncture as part of comprehensive cancer care should seek a qualified, licensed acupuncturist experienced in oncology support.

This comprehensive review examines the intersection of nanotechnology and gut microbiota manipulation in cancer immunotherapy. The authors synthesized current literature demonstrating the bidirectional relationship between gut microbiota and immune checkpoint inhibitor (ICI) efficacy through the "microbiota-immune-tumor" axis. Key findings indicate that while gut microbiota significantly influences tumor progression and treatment response, traditional interventions (fecal microbiota transplantation, antibiotics) lack precise targeting capabilities. Nanotechnology platforms overcome these limitations by enabling targeted gut microbiota modulation, reshaping the tumor immune microenvironment, and reversing multidrug resistance in chemotherapy, radiotherapy, and targeted therapies. The review highlights synergistic applications combining nanoparticles with probiotics and extracellular vesicles. Clinical relevance: Understanding microbiota-immune crosstalk may inform integrative oncology approaches. Practitioners supporting cancer patients should consider how interventions affecting gut health may influence conventional treatment efficacy, though specific sample sizes and effect measurements were not provided in this narrative review.